ÂÜÀòÂÒÂ×

Doug Sheehy is a senior biotechnology executive who has managed global legal and compliance operations for multiple companies. Prior to joining Sonoma, Sheehy served as General Counsel and Secretary for Aimmune Therapeutics, Inc., a publicly-traded biopharmaceutical company that develops and commercializes treatments for potentially life-threatening food allergies. Aimmune’s lead product, PALFORZIA®, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of peanut allergy in 2020. Aimmune was acquired by Nestle Health Science for $2.6 billion in late 2020. Sheehy previously served as Executive Vice President, Chief Administrative Officer, General Counsel, and Secretary of Codexis, Inc., a publicly traded biotechnology company that develops novel treatments for rare diseases and industrial synthetic enzymes for the pharmaceutical and food industries. Prior to Codexis, Sheehy served as Executive Director, Legal at CV Therapeutics, Inc., a publicly-traded biopharmaceutical company that developed and commercialized treatments for cardiovascular disease. He started his career as a corporate and securities lawyer in Silicon Valley representing emerging growth companies and venture funds at Gunderson Dettmer.

Sheehy received an A.B. in History from Dartmouth College and a J.D. from American University’s Washington College of Law, where he was Editor-in-Chief of the American University Law Review.